1.
Raichle M: The pathophysiology of brain ischemia. Ann Neurol 1983;13:2–10.
2.
Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia. J Neurosurg 1992;77:169–184, 337–354.
3.
Del Zoppo GJ, Zeumer H, Harker LA: Thrombolytic therapy in stroke: Possibilities and hazard. Stroke 1986;17:595–607.
4.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
5.
Hommel M, Bogousslavsky J: Thrombolytics in acute cerebral ischemia. Exp Opin Invest Drugs 1994;3:1011–1020.
6.
Caplan LR, Mohr JP, Kistler JP, Koroshetz W: Thrombolysis – Not a panacea for ischemic stroke. N Engl J Med 1997;337:1309–1310.
7.
Grotta J: The best current option for most patients. N Engl J Med 1997;337:1310–1312.
8.
Multicenter Acute Stroke Trial-Italy (MAST-I) Group: Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509–1514.
9.
Multicenter Acute Stroke Trial-Europe (MAST-E) Study Group: Fibrinolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145–150.
10.
Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeill JJ, Rosen D, Stewart-Wynne EG, Tuck RR, for the Australian Streptokinase (ASK) Trial Study Group: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961–966.
11.
European Cooperative Acute Stroke Study (ECASS): Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017–1025.
12.
ECASS-II, Second European-Australasian Acute Stroke Study Investigators: Randomized double-blind placebo-controlled trial of fibrinolytic therapy with intravenous alteplase in acute ischemic stroke. Lancet 1998;352:1245–1251.
13.
Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W: Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167–1174.
14.
Quality Standard Subcommittee of the American Academy of Neurology (AAN): Thrombolytic therapy for acute ischemic stroke: Summary statement. Neurology 1996;47:835–839.
15.
Devuyst G, Bogousslavsky J: Recent progress in drug treatment for acute stroke. J Neurol Neurosurg Psychiatry 1999;67:420–424.
16.
Streiner TR, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W: The ECASS 3-hour cohort: Secondary analysis of ECASS data by time stratification. Cerebrovasc Dis 1998;8:198–203.
17.
Wardlaw JM, Warlow CP, Counsell C: Systematic review of evidence on fibrinolytic therapy for acute ischemic stroke. Lancet 1997;350:607–614.
18.
Ford G, Freemantle N: ECASS-II intravenous alteplase in acute ischemic stroke (letter). Lancet 1999;353:65–68.
19.
Davalos A, on behalf of the ECASS-II Spanish Group: Fibrinolytic therapy for acute stroke: The Spanish experience. Cerebrovasc Dis 1999;9(suppl 3):9–15.
20.
Clark WM, Albers GW, for the ATLANTIS Stroke Study Investigators: The Atlantis rt-PA (alteplase) acute stroke trial: Final results. Stroke 1999;39:234.
21.
Osborn TM, LaMonte MP, Gaasch WR: Intravenous thrombolytic therapy for stroke: A review of recent studies and controversies. Ann Emerg Med 1999;34:244–255.
22.
Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M: PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4–11.
23.
Furlan AJ, Higashida R, Wechsler L, Schulz G, for the PROACT Investigators: PROACT-II: Recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. The PROACT-II Investigators. Stroke 1999;30:234.
24.
Wardlaw JM, Yamaguchi T, Del Zoppo GJ: Thrombolysis for acute ischemic stroke (Cochrane Review); in: The Cochrane Library, ed 2. Oxford, Update Software, 1999.
25.
Minematsu K, Fisher M, Li L, Sotak CH: Diffusion and perfusion MRI studies to evaluate a non-competitive NMDA antagonist and reperfusion in experimental stroke. Stroke 1993;24:2074–2081.
26.
Albers GW: Expanding the window for thrombolytic therapy in acute stroke: The potential role of acute MRI for patient selection. Stroke 1999;30:2230–2237.
27.
Brott TG, Hacke W: Thrombolytic and defibrinogenating agents for ischemic and hemorrhagic stroke; in Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds): Stroke: Pathophysiology, Diagnosis, and Management. New York, Churchill Livingstone, 1998, pp 1155–1176.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.